FACT Biomarker Subgroup Analysis

CompletedOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

December 19, 2011

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Pre-Eclampsia
Interventions
OTHER

4.0mg Folic Acid received through participation in FACT (NCT01355159)

"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid"

OTHER

Placebo received through participation in FACT

"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration."

Trial Locations (4)

E1C 6Z8

The Moncton Hospital, Moncton

K7L 2V7

Kingston General Hospital, Kingston

K1Y 4E9

The Ottawa Hospital, Ottawa

Unknown

Health Canada, Ottawa

All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER